{"protocolSection": {"identificationModule": {"nctId": "NCT01346072", "orgStudyIdInfo": {"id": "TOLCOPEP11"}, "organization": {"fullName": "University of North Carolina, Chapel Hill", "class": "OTHER"}, "briefTitle": "Pilot Study of Using Copeptin to Predict Response to Tolvaptan", "officialTitle": "Pilot Study of the Relationship of Ambient Copeptin to the Aquaretic Effects of Tolvaptan in Patients With Heart Failure"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-04"}, "primaryCompletionDateStruct": {"date": "2014-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-04-29", "studyFirstSubmitQcDate": "2011-04-29", "studyFirstPostDateStruct": {"date": "2011-05-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-02-24", "resultsFirstSubmitQcDate": "2017-04-11", "resultsFirstPostDateStruct": {"date": "2017-05-17", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-04-11", "lastUpdatePostDateStruct": {"date": "2017-05-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Kirkwood Adams", "investigatorTitle": "Associate Professor of Medicine and Radiology", "investigatorAffiliation": "University of North Carolina, Chapel Hill"}, "leadSponsor": {"name": "University of North Carolina, Chapel Hill", "class": "OTHER"}, "collaborators": [{"name": "Otsuka America Pharmaceutical", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This pilot study will investigate the association between levels of the peptide copeptin and response to tolvaptan, a drug that blocks the action of the water retaining hormone vasopressin. The study will enroll stable outpatients with CHF with reduced LVEF (\u226445) selected by targeting upper and lower quartile copeptin levels at screening (10 each). The treatment phase of the study will be a prospective, single-arm, open label protocol. All patients will receive active therapy consisting of a single oral dose of 30 mg of tolvaptan with body weight, fluid intake, and urine output monitored in a research unit for 24 hours.\n\nFor analysis of study endpoints, patients in the single intervention arm will be stratified by a prospectively determined cut-point of copeptin level into two groups (\u226510 versus \\<10 pmol/L). The copeptin level used for the two group stratification will be the blinded copeptin value obtained at baseline from the hospital phase prior to administration of tolvaptan.", "detailedDescription": "The study screening strategy will be designed to enroll an enriched patient population by identifying patients at the high or low end of the spectrum of copeptin levels for outpatients with stable heart failure. This will be accomplished by blinded review of copeptin levels obtained during screening.\n\nThe primary endpoints for analysis will be 24 hour urine output and the change in body weight over 24 hours during the inpatient stay."}, "conditionsModule": {"conditions": ["Cardiovascular Diseases", "Heart Diseases", "Heart Failure"], "keywords": ["tolvaptan", "copeptin", "heart failure", "vasopressin antagonist"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 21, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Tolvaptan", "type": "OTHER", "description": "Single arm study", "interventionNames": ["Drug: tolvaptan"]}], "interventions": [{"type": "DRUG", "name": "tolvaptan", "description": "oral, 30 mg, single dose, one time administration", "armGroupLabels": ["Tolvaptan"], "otherNames": ["Samsca"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Urine Output", "description": "Total urine output for 24 hours following tolvaptan administration", "timeFrame": "24 hours"}, {"measure": "Body Weight", "description": "Change in body weight from baseline to 24 hours after tolvaptan administration", "timeFrame": "Change over 24 hours"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and female patients with a history of chronic symptomatic heart failure, defined as dyspnea on exertion or edema, due to cardiac dysfunction, of at least one month's duration\n2. Left ventricular ejection fraction \u2264 45% as documented by quantitative assessment by an accepted imaging technique within one year of screening\n3. Meet baseline copeptin criteria for entry\n4. Currently taking a diuretic (with diuretic defined as any loop or thiazide diuretic or aldosterone antagonist at any dose)\n\nExclusion Criteria:\n\n1. Current New York Heart Association Functional Class IV heart failure\n2. Patients who are felt to be volume depleted based on clinical examination or need to reduce diuretic administration\n3. Presence of clinical contraindications to tolvaptan\n4. Episode of acute myocardial infarction or acute coronary syndrome within the past 3 months\n5. Cardiovascular surgical procedure within the past 4 weeks\n6. CHF due to uncorrected thyroid disease, active myocarditis, or known amyloid cardiomyopathy.\n7. History of primary significant liver disease or acute hepatic failure, as defined by the investigator.\n8. Chronic uncontrolled diabetes mellitus as determined by the investigator.\n9. Supine systolic arterial blood pressure \\< 90 mmHg at screening\n10. Serum creatinine \\> 3.5 mg/dL at screening\n11. Serum potassium \\> 5.5 mEq/L or \\< 3.5 mEq/L at screening\n12. Subjects currently treated with hemofiltration or dialysis\n\nj. Subjects judged by the investigator to be unable to maintain accurate intake and output during their hospitalization related to medical or other problems", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Kirkwood F Adams, MD", "affiliation": "University of North Carolina, Chapel Hill", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of North Carolina at Chapel Hill", "city": "Chapel Hill", "state": "North Carolina", "zip": "27514", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Blinded copeptin results were reviewed in 43 patients for participation in the hospital phase. 11 patients were selected by targeting the upper quartile of baseline copetin and 10 patients by targeting the lower quartile of screening copeptin levels. A total of 21 patients were enrolled in hospital phase.", "recruitmentDetails": "100 patients were screened in two periods approximately six months each in duration at a dedicated Heart Failure Clinic at the University of North Carolina Chapel Hill. 43 patients met inclusion/exclusion criteria and had a blood sample sent for copeptin testing. Twenty-one patients were enrolled in the hospital phase of the study.", "groups": [{"id": "FG000", "title": "Tolvaptan High Copeptin", "description": "Tolvaptan: oral, 30 mg, single dose, one time administration\n\nHigh Copeptin \u2265 10 pmol/L at baseline"}, {"id": "FG001", "title": "Tolvaptan Low Copeptin", "description": "Tolvaptan: oral, 30 mg, single dose, one time administration\n\nLow Copeptin \\< 10 pmol/L at baseline"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All patients in Low Copeptin group were included in analysis. One patient in High Copeptin group had reduced renal function at baseline versus screening and transient hypovolemia during hospitalization indicative of volume depletion. This patient was excluded prior to review of blinded copeptin results and study data analysis for a final N of 20.", "groups": [{"id": "BG000", "title": "Tolvaptan High Copeptin", "description": "Tolvaptan: oral, 30 mg, single dose, one time administration\n\nHigh Copeptin \u2265 10 pmol/L at baseline"}, {"id": "BG001", "title": "Tolvaptan Low Copeptin", "description": "Tolvaptan: oral, 30 mg, single dose, one time administration\n\nLow Copeptin \\< 10 pmol/L at baseline"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "20"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "14"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60", "spread": "11"}, {"groupId": "BG001", "value": "59", "spread": "13"}, {"groupId": "BG002", "value": "60", "spread": "12"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "11"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "8"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "20"}]}]}]}, {"title": "LVEF", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "23", "spread": "6.0"}, {"groupId": "BG001", "value": "31", "spread": "11"}, {"groupId": "BG002", "value": "27", "spread": "9.6"}]}]}]}, {"title": "Baseline Copeptin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "20.5", "spread": "8.7"}, {"groupId": "BG001", "value": "5.7", "spread": "1.9"}, {"groupId": "BG002", "value": "13.1", "spread": "9.7"}]}]}]}, {"title": "Serum Creatinine", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.18", "spread": "0.23"}, {"groupId": "BG001", "value": "1.03", "spread": "0.35"}, {"groupId": "BG002", "value": "1.10", "spread": "0.30"}]}]}]}, {"title": "Serum Sodium", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mEq/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "141.1", "spread": "2.28"}, {"groupId": "BG001", "value": "140.8", "spread": "3.46"}, {"groupId": "BG002", "value": "141.0", "spread": "2.86"}]}]}]}, {"title": "Total Daily Dose of Loop Diuretic", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "124", "spread": "104"}, {"groupId": "BG001", "value": "47", "spread": "46"}, {"groupId": "BG002", "value": "84", "spread": "86"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Urine Output", "description": "Total urine output for 24 hours following tolvaptan administration", "populationDescription": "All patients in the Low Copeptin group were included in the analysis. One patient in the High Copeptin group had reduced renal function at baseline versus screening and transient hypovolemia during hospitalization indicative of volume depletion. This patient was excluded prior to review of blinded copeptin results and study data analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "Tolvaptan High Copeptin", "description": "Tolvaptan: oral, 30 mg, single dose, one time administration\n\nHigh Copeptin \u2265 10 pmol/L at baseline"}, {"id": "OG001", "title": "Tolvaptan Low Copeptin", "description": "Tolvaptan: oral, 30 mg, single dose, one time administration\n\nLow Copeptin \\< 10 pmol/L at baseline"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6498", "spread": "2328"}, {"groupId": "OG001", "value": "5784", "spread": "1835"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.853", "statisticalMethod": "Wilcoxon Two-Sample Test", "statisticalComment": "Wilcoxon Two Sample Test was used with Exact Test two sided p value reported"}]}, {"type": "PRIMARY", "title": "Body Weight", "description": "Change in body weight from baseline to 24 hours after tolvaptan administration", "populationDescription": "All patients in the Low Copeptin group were included in the analysis. One patient in the High Copeptin group had reduced renal function at baseline versus screening and transient hypovolemia during hospitalization indicative of volume depletion. This patient was excluded prior to review of blinded copeptin results and study data analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Kg", "timeFrame": "Change over 24 hours", "groups": [{"id": "OG000", "title": "Tolvaptan High Copeptin", "description": "Tolvaptan: oral, 30 mg, single dose, one time administration\n\nHigh Copeptin \u2265 10 pmol/L at baseline"}, {"id": "OG001", "title": "Tolvaptan Low Copeptin", "description": "Tolvaptan: oral, 30 mg, single dose, one time administration\n\nLow Copeptin \\< 10 pmol/L at baseline"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.3", "spread": "1.0"}, {"groupId": "OG001", "value": "-0.4", "spread": "1.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.035", "statisticalMethod": "Wilcoxon Two-Sample Test", "statisticalComment": "Wilcoxon Two Sample Test was used with Exact Test two sided p value reported"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "24 hours", "eventGroups": [{"id": "EG000", "title": "Tolvaptan High Copeptin", "description": "Tolvaptan: oral, 30 mg, single dose, one time administration\n\nHigh Copeptin \u2265 10 pmol/L at baseline", "deathsNumAffected": 0, "deathsNumAtRisk": 11, "seriousNumAffected": 0, "seriousNumAtRisk": 11, "otherNumAffected": 0, "otherNumAtRisk": 11}, {"id": "EG001", "title": "Tolvaptan Low Copeptin", "description": "Tolvaptan: oral, 30 mg, single dose, one time administration\n\nLow Copeptin \\< 10 pmol/L at baseline", "deathsNumAffected": 0, "deathsNumAtRisk": 10, "seriousNumAffected": 0, "seriousNumAtRisk": 10, "otherNumAffected": 0, "otherNumAtRisk": 10}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Kirkwood F. Adams, Jr., MD", "organization": "University of North Carolina Chapel Hill", "email": "kfa@med.unc.edu", "phone": "919-966-2877"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003919", "term": "Diabetes Insipidus"}, {"id": "D000006333", "term": "Heart Failure"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006331", "term": "Heart Diseases"}], "ancestors": [{"id": "D000007674", "term": "Kidney Diseases"}, {"id": "D000014570", "term": "Urologic Diseases"}, {"id": "D000052776", "term": "Female Urogenital Diseases"}, {"id": "D000005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000052801", "term": "Male Urogenital Diseases"}, {"id": "D000010900", "term": "Pituitary Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M9419", "name": "Heart Diseases", "asFound": "Heart Disease", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M7114", "name": "Diabetes Insipidus", "asFound": "Copeptin", "relevance": "HIGH"}, {"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M10698", "name": "Kidney Diseases", "relevance": "LOW"}, {"id": "M17319", "name": "Urologic Diseases", "relevance": "LOW"}, {"id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW"}, {"id": "M27093", "name": "Female Urogenital Diseases", "relevance": "LOW"}, {"id": "M14127", "name": "Pregnancy Complications", "relevance": "LOW"}, {"id": "M8399", "name": "Female Urogenital Diseases and Pregnancy Complications", "relevance": "LOW"}, {"id": "M27095", "name": "Male Urogenital Diseases", "relevance": "LOW"}, {"id": "M13791", "name": "Pituitary Diseases", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077602", "term": "Tolvaptan"}], "ancestors": [{"id": "D000065092", "term": "Antidiuretic Hormone Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M17414", "name": "Vasopressins", "relevance": "LOW"}, {"id": "M4437", "name": "Arginine Vasopressin", "relevance": "LOW"}, {"id": "M1858", "name": "Tolvaptan", "asFound": "Total volume", "relevance": "HIGH"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Coag", "name": "Coagulants"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}